CD274 and cancer: The United States of America Food and Drug Administration (FDA) has approved PD-1/PD-L1 inhibitors to treat nine cancer types, including melanoma, non-small cell lung cancer, urothelial cancer, renal cell carcinoma, microsatellite instability or mismatch repair-deficient gastric cancer, colorectal cancer, hepatocellular carcinoma, and Merkel cell carcinoma (30–33).